Monoclonal antibody and Fc fusion protein drugs are complex heterogeneous mixtures of
numerous different protein variants and modifications. N-glycosylation as one of the most …

Understanding the impact of glycosylation and keeping a close control on glycosylation of
product candidates are required for both novel and biosimilar monoclonal antibodies (mAbs) …

Therapeutic antibodies (IgG-type) contain several post-translational modifications (PTMs)
whereby introducing a large heterogeneity, both structural and functional, into this class of …

The development of recombinant therapeutic proteins has been a major revolution in
modern medicine. Therapeutic-based monoclonal antibodies (mAbs) are growing rapidly …

Glycosylation is one of the structurally diverse and complex forms of post translational
modifications observed in proteins which influence the effector functions of IgG-Fc. Although …

N-glycosylation of therapeutic antibodies starts as a co-translational step followed by a set of
post-translational modifications and is considered as one of the critical quality attributes …

Glycosylation of the conserved asparagine residue in each heavy chain of IgG in the CH2
domain is known as N-glycosylation. It is one of the most common post-translational …

Monoclonal antibodies are increasingly being developed to treat multiple disease areas,
including those related to oncology, immunology, neurology, and ophthalmology. There are …

Previous studies on the effect of glycosylation on the elimination rate of antibodies have
produced conflicting results. Here, we performed pharmacokinetic studies in mice with two …

Monoclonal antibodies (MAbs) are the fastest growing class of human pharmaceuticals.
More than 20 MAbs have been approved and several hundreds are in clinical trials in …